Matthew S. Dietz

Matthew S. Dietz, DO, MSEd

Languages spoken: English

Clinical Locations

Primary Children's Hospital

801-662-1000

  • Dr. Dietz’s clinical interests include caring for pediatric and young adult patients with bone and soft tissue sarcoma. He received his degrees in medicine and medical education from the University of New England. He completed his Pediatric residency and Hematology and Oncology fellowship at Oregon Health & Science University where he also served as chief resident.

    In 2020 Dr. Dietz joined the faculty of the University of Utah, where he is currently an Assistant Professor of Pediatrics in the Division of Pediatric Hematology and Oncology. He is a member of the solid tumor team at the University of Utah and Primary Children’s Hospital.

    Dr. Dietz’s research efforts involve collaboration with basic and translational researchers to better understand the biology driving cancer progression. Additional interests include developing early phase clinical trials with new therapeutic agents to better treat aggressive cancers. He is involved in multiple clinical trial consortia including the Children’s Oncology Group, The Sunshine Project and the Pediatric Oncology Experimental Therapeutics Investigator’s Consortium.

    Specialties

    Board Certification

    American Board of Pediatrics (Pediatrics)
    American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)

  • Dr. Dietz’s clinical interests include caring for pediatric and young adult patients with bone and soft tissue sarcoma. He received his degrees in medicine and medical education from the University of New England. He completed his Pediatric residency and Hematology and Oncology fellowship at Oregon Health & Science University where he also served as chief resident.

    In 2020 Dr. Dietz joined the faculty of the University of Utah, where he is currently an Assistant Professor of Pediatrics in the Division of Pediatric Hematology and Oncology. He is a member of the solid tumor team at the University of Utah and Primary Children’s Hospital.

    Dr. Dietz’s research efforts involve collaboration with basic and translational researchers to better understand the biology driving cancer progression. Additional interests include developing early phase clinical trials with new therapeutic agents to better treat aggressive cancers. He is involved in multiple clinical trial consortia including the Children’s Oncology Group, The Sunshine Project and the Pediatric Oncology Experimental Therapeutics Investigator’s Consortium.

    Board Certification and Academic Information

    Academic Departments Pediatrics -Primary
    Board Certification
    American Board of Pediatrics (Pediatrics)
    American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)

    Education history

    Graduate Training Human Investigations - Oregon Health & Science University Certificate
    Pediatric Hematology/Oncology - Oregon Health & Science University Fellow
    Residency Pediatrics - Oregon Health & Science University Chief Resident
    Pediatrics - Oregon Health & Science University Intern/Resident
    Graduate Training Medical Education - University of New England College of Osteopathic Medicine M.S.
    Osteopathic Medicine - University of New England College of Osteopathic Medicine D.O.
    Undergraduate Chemistry - Franklin & Marshall College B.A.

    Selected Publications

    Journal Article

    1. McMahon NP, Jones JA, Anderson AN, Dietz MS, Wong MH, Gibbs SL (2023). Flexible Cyclic Immunofluorescence (cyCIF) Using Oligonucleotide Barcoded Antibodies. Cancers, 15(3).
    2. Dietz MS, Sutton TL, Walker BS, et al (2021). Relevance of circulating hybrid cells as a non-invasive biomarker for myriad solid tumors. Sci Rep, 11(13630).
    3. Dietz MS, Beach CZ, Barajas R, Parappilly MS, Sengupta SK, Baird LC, Ciporen JN, Han SJ, Loret de Mola R, Cho YJ, Nazemi KJ, McClelland S 3rd, Wong MH, Jaboin JJ (2020). Measure Twice: Promise of Liquid Biopsy in Pediatric High-Grade Gliomas. Adv Radiat Oncol, 5(2), 152-162.
    4. Lamble AJ, Dietz M, Laderas T, McWeeney S, Lind EF (2017). Integrated functional and mass spectrometry-based flow cytometric phenotyping to describe the immune microenvironment in acute myeloid leukemia. J Immunol Methods, 453, 44-52.
    5. Dietz M, Jones M, Svoboda M, Finanger E (2016). Case 3: Episodic Weakness in an 18-month-old Girl. Pediatr Rev, 37(5), 218-9.

    Review

    1. Vagher J, Dietz MS, Schiffman JD, Kohlmann W, Maese L (2022). Germline Predisposition to Soft Tissue Sarcoma. [Review]. Journal of Cancer Metastasis and Treatment, 8(31).